Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Rhea-AI Summary

Climb Bio (Nasdaq: CLYM) has announced that it will present data at the American Society of Nephrology Kidney Week 2024, taking place in San Diego, CA from October 23-27, 2024. The presentation will feature a poster titled 'A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy'.

The presenter will be Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center, Chief of the Division of Nephrology at St. Peter's Hospital, Chief of Clinical Research at St. Peter's Health Partners, and Clinical Scientist at Massachusetts General Hospital. The poster session, focusing on Membranous Nephropathy, FSGS, and Minimal Change Disease, is scheduled for October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT, with the poster board number TH-PO587.

Positive

• Climb Bio's research on Budoprutug, an anti-CD19 monoclonal antibody, selected for presentation at a major nephrology conference
• Study focuses on Primary Membranous Nephropathy, potentially expanding Climb Bio's therapeutic reach in kidney diseases

Negative

• None.

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

Poster Presentation

A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy
Presenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;
Chief, Division of Nephrology, St. Peter's Hospital; Chief, Clinical Research, St. Peter's Health Partners;
Clinical Scientist, Massachusetts General Hospital
Session Title: Membranous Nephropathy, FSGS, and Minimal Change Disease [PO1402-1]
Session Date, Time: October 24, 2024 from 10:00 a.m. to 12:00 p.m. PT
Poster Board #: TH-PO587

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Westwicke
339-970-2843

Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375

FAQ

What is Climb Bio presenting at the American Society of Nephrology Kidney Week 2024?

Climb Bio is presenting a poster titled 'A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy' at the conference.

When and where is the American Society of Nephrology Kidney Week 2024 taking place?

The American Society of Nephrology Kidney Week 2024 is taking place in San Diego, CA from October 23-27, 2024.

Who is presenting Climb Bio's (CLYM) research at the Kidney Week 2024?

Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center and Chief of the Division of Nephrology at St. Peter's Hospital, will be presenting the research.

What is the specific date and time for Climb Bio's (CLYM) poster presentation at Kidney Week 2024?

Climb Bio's poster presentation is scheduled for October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT.